Hsbc Holdings PLC Has $213,000 Holdings in Glaukos Co. (NYSE:GKOS)

Hsbc Holdings PLC decreased its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 79.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,419 shares of the medical instruments supplier's stock after selling 5,612 shares during the period. Hsbc Holdings PLC's holdings in Glaukos were worth $213,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in Glaukos during the fourth quarter worth approximately $43,000. Asset Planning Inc purchased a new position in Glaukos in the fourth quarter valued at about $90,000. Picton Mahoney Asset Management purchased a new position in Glaukos in the 4th quarter worth approximately $125,000. SBI Securities Co. Ltd. acquired a new stake in Glaukos in the fourth quarter valued at approximately $153,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after purchasing an additional 807 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of NYSE GKOS traded down $0.47 during midday trading on Thursday, hitting $91.11. The company's stock had a trading volume of 126,361 shares, compared to its average volume of 931,849. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The firm's fifty day moving average price is $94.05 and its 200-day moving average price is $126.57. The firm has a market cap of $5.21 billion, a P/E ratio of -31.74 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. During the same period in the prior year, the company posted ($0.70) EPS. The business's revenue for the quarter was up 24.6% compared to the same quarter last year. On average, sell-side analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Stephens lowered their price target on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Mizuho lowered their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Wells Fargo & Company cut Glaukos from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. Morgan Stanley lowered their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus cut their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

Insider Activity

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. The trade was a 4.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77% decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is owned by insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.